Why the study?
Does high-dose cyclophosphamide cause echocardiographic changes and cardiotoxicity in pediatric patients?
Population
40 pediatric patients treated for solid tumors and prior to marrow transplant.
Design
Cohort
Follow-up
Days to weeks
Authors
Loading...
May warrant closer echocardiographic surveillance with high-dose cyclophosphamide after anthracyclines in children; leaves open causality and optimal thresholds.
Does high-dose cyclophosphamide cause echocardiographic changes and cardiotoxicity in pediatric patients?
High-dose cyclophosphamide (≥170 mg/kg/week, or ≥120 mg/kg/week in those with prior anthracycline exposure) frequently causes significant echocardiographic changes and pericardial effusion in pediatric patients.
Steinherz et al. (1981) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: